Otsuka Pharmaceutical To Acquire Astex Pharmaceuticals - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Otsuka Pharmaceutical To Acquire Astex Pharmaceuticals
Otsuka's planned acquisition bolsters its pipeline in oncology and adds fragment-based drug-discovery technology.


The Japanese pharmaceutical company Otsuka Pharmaceutical has agreed to acquire Astex Pharmaceuticals, a company specializing in small-molecule drug development with a focus on oncology, for $886 million. The deal will proceed through an all-cash tender offer by Otsuka followed by a second-step merger through Otsuka America Inc., the company's US subsidiary, according to a Sept. 5, 2013 Otsuka press release. Otsuka expects to close the transaction early in the fourth quarter of 2013, subject to the satisfaction of customary closing conditions, according to a Sept. 5, 2013 Astex Pharmaceuticals press release.

Astex Pharmaceuticals' lead commercial product is Dacogen (decitabine), used to treat myelodysplastic syndromes and elderly acute myeloid leukemia. It has eight drugs in clinical development, four in Phase I development and four in Phase II development. It also holds fragment-based drug-discovery technology that evaluates the binding of target proteins with small molecules by 3D structural analysis, an improved approach, Otsuka says, over current high-throughput screening technology for measuring pharmacological activity. The technology to combine these small fragments makes it possible to discover lead compounds more quickly, according to the company.

For purposes of the transaction, the initial tender offer period will begin within 10 business days after Sept. 5, 2013 and end 20 business days thereafter. Under certain circumstances, Otsuka will be obligated to extend the tender offer to no later than Jan. 31, 2014. Otsuka has established an acquisition vehicle, Autumn Acquisition Corporation, for purposes of the acquisition. After the tender offer has concluded, Autumn Acquisition Corporation will merge with and into Astex, and Astex will become Otsuka America’s direct wholly owned subsidiary and an indirect wholly owned subsidiary of Otsuka.

Source: Otsuka Pharmaceutical and Astex Pharmaceuticals

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here